The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20141096: Marathon Petroleum Corporation; Hess Corporation
20141045: Danaher Corporation; Paul D. Porteous
20141054: Marcato International Ltd.; InterContinental Hotels Group PLC
20141055: Marcato, L.P.; InterContinental Hotels Group PLC
20141067: Henkel AG & Co. KGaA; TSG5 L.P.
20141071: Albany Molecular Research, Inc.; Altaris Health Partners II, L.P.
20141075: TransForce Inc.; Marathon Fund Limited Partnership V
20141076: NRG Energy, Inc.; Terra-Gen Power Holdings, LLC
20141086: Google Inc.; Skybox Imaging, Inc.
20141089: Quartet Merger Corp.; Pangaea Logistics Solutions Ltd.
20141090: NGL Energy Partners LP; Morgan Stanley
20141091: Steven A. Ballmer; Rochelle H. & Donald T. Sterling
20141095: Phillips 66; Chevron Corporation
20141101: Riverstone Global Energy and Power Fund V (FT), L.P.; RJS Power Holdings LLC
20141107: Linden Capital Partners II, LP; Kersdale Holdings, LLC
20141113: Avista Capital Partners II, L.P.; Avista Capital Partners II, L.P.
Akorn and Hi-Tech Pharmacal, In the Matter of
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. agreed to sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle FTC charges that Akorn’s proposed $640 million acquisition of Hi-Tech would be anticompetitive and lead to higher prices for consumers. The proposed order requires the parties to sell either Akorn’s or Hi-Tech’s rights and assets to each of the five drug products to Watson, and requires Akorn to assign Watson its contract for making branded and generic EMLA cream within 10 days after the deal is consummated. In addition, the companies must maintain the drugs to be sold as viable, marketable, and competitive pending their divestiture, and must allow the FTC to appoint a monitor to ensure that the companies comply with the order’s requirements.